1[1]TREASURE C B,KLEIN J L,WEINTRAUB W S,et al.Beneficial effects of cholesterol-lowering therapy on the coronary on the endothelium in patients with coronary artery disease[J].N Engl J Med,1995,332(8):481-487.
2[2]ANDERSON T,MEREDITH I,YEUNG A,et al.The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary[J].N Engl J Med,1995,332(8):488-493.
3[3]DUPUIS J,TARDIF J,CERNACEK P,et al.Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes:the RECIFE(Reduction of cholesterol in Ischemia and Function of the Endothelium)trial[J].Circulation,1999,99(25):3227-3233.
4[4]ULRICH L,FATA V L,PLUTZKY J,et al.Upregulation of endotheliual nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulation,1998,97(12):1129-1135.
5[5]LACOSTE L,LAM J Y,HUNG J,et al.Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction[J].Circulation,1995,92(1):3127-3177.
6[6]RIDKER P M,CUSHSHMAN M,STAMPFER M J,et al.Inflammation,aspirin and risk of cardiovascular disease in apparently healthy men[J].N Engl J Med,1997,336(14):973-979.
7[7]BICKEL C,RUPPRECHTT H J,BLANKENBERG S,et al.Non-lipid lowering effects of statin medication in patients with coronary heart disease[J].J Am Coll Cardiol,2000,35(1):256A.
8[8]INOUE I,GOTO S,MIZOTANI K,et al.Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of MRNA levels for interleukin-1β,interleukin-6,cyclooxygenase-2,and p22phox by regulation of peroxisome proliferator-activated receptorα(PPARα)in primary endothelial cells[J].Life sciences,2000,67(8):863-876.
9[9]SINDERMANN J,WEIGEL K,MULLER J G,et al.Induction of p53 and interleukin by HMG CoA reductase inhibitors in human coronary smooth muscle cells[J].EurHeartJ,1997,18(3):371.
